Rhythm Pharmaceuticals Inc
Follow $RYTM
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $RYTM by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is RYTM moving today?
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
RYTM overview
Related filings and maps
Congress activity in RYTM
No receipt-qualified Congressional disclosure is present for RYTM in the cached public ledger.
RYTM contract awards, year to date.
Public federal awards linked to this ticker.
RYTM lobbying filings, year to date.
Registered lobbying filings matched to Rhythm Pharmaceuticals Inc.